

#3
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83408

Kousuke TANI, et al.

Appln. No.: National Stage Entry of PCT/JP03/02478

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: September 03, 2004

Examiner: Unknown

For: 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT
COMPRISING THE COMPOUND AS ACTIVE INGREDIENT

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with

INFORMATION DISCLOSURE STATEMENT
National Stage Entry of PCT/JP03/02478.

an English-language version (if not already included) of at least that portion of the
Communication indicating the degree of relevance found by the foreign patent office.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3)
for foreign language documents, Applicant submits the following explanations:

US Patent 5,310,499 corresponds to EP 471201.

EP 1 132 086 corresponds to JP-A-2001-233792.

EP 1 121 939 corresponds to JP-A-2001-220357.

EP 1 190 949 corresponds to JP-A-2001-181210.

The submission of the listed documents is not intended as an admission that any such
document constitutes prior art against the claims of the present application. Applicant does
not waive any right to take any action that would be appropriate to antedate or otherwise
remove any listed document as a competent reference against the claims of the present
application.

The USPTO is directed and authorized to charge all required fees, except for the Issue
Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any
overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Mark Boland #41,574
Registration No. 32,197

Date: September 3, 2004

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	National Stage Entry of PCT/JP03/02478
				Confirmation Number	Unknown
				Filing Date	September 03, 2004
				First Named Inventor	Kousuke TANI
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	Q83408

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,310,499		05-10-1994	SCHEROWSKY ET AL.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	03/009872	A	02-06-2003	Ono Pharmaceutical Co., Ltd	
		WO	03/008377	A	01-30-2003	F. HOFFMANN-LA ROCHE AG	
		WO	02/42268	A	05-03-2002	PFIZER PRODUCTS	
		EP	471201	A	02-19-1992	HOECHST AG	
		WO	03/007941	A	01-30-2003	F. HOFFMANN-LA ROCHE AG	
		WO	02/24647	A	03-28-2002	Ono Pharmaceutical Co., Ltd	
		JP	2001-233792	A	08-28-2001	Pfizer Products Inc.	
		JP	2001-220357	A	08-14-2001	Pfizer Products Inc.	
		JP	2001-181210	A	07-03-2001	Pfizer Products Inc.	
		EP	1132086	A			
		EP	1121939	A			
		EP	1110949	A			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.